MedKoo Biosciences/Navitoclax (ABT263)/201970/25mg

Synonym:ABT263;ABT-263;ABT263;Navitoclax

IUPAC/ChemicalName:(R)-4-(4-((4-chloro-4,4-dimethyl-3,4,5,6-tetrahydro-[1,1-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((4-((4-morpholino-1-(phenylthio)butan-2-yl)amino)-3-((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide

InChiKey:JLYAXFNOILIKPP-KXQOOQHDSA-N

InChiCode:InChI=1S/C47H55ClF3N5O6S3/c1-46(2)20-18-42(34-8-12-37(48)13-9-34)36(31-46)32-55-22-24-56(25-23-55)39-14-10-35(11-15-39)45(57)53-65(60,61)41-16-17-43(44(30-41)64(58,59)47(49,50)51)52-38(19-21-54-26-28-62-29-27-54)33-63-40-6-4-3-5-7-40/h4-17,30,38,52H,18-29,31-33H2,1-2H3,(H,53,57)/t38-/m1/s1

SMILESCode:O=C(NS(=O)(C1=CC=C(N[C@H](CCN2CCOCC2)CSC3=CC=CC=C3)C(S(=O)(C(F)(F)F)=O)=C1)=O)C4=CC=C(N5CCN(CC6=C(C7=CC=C(Cl)C=C7)CCC(C)(C)C6)CC5)C=C4

TechnicalData

AdditionalInformation

Bcl-2,Bcl-XL,andBcl-warefrequentlyoverexpressedinawidevarietyofcancers,includingthoseofthelymphaticsystem,breast,lung,prostate,andcolon,andhavebeenlinkedtotumordrugresistance.

References

1:KaeferA,YangJ,NoertersheuserP,MensingS,HumerickhouseR,AwniW,XiongH.Mechanism-basedpharmacokinetic/pharmacodynamicmeta-analysisofnavitoclax(ABT-263)inducedthrombocytopenia.CancerChemotherPharmacol.2014Sep;74(3):593-602.doi:10.1007/s00280-014-2530-9.Epub2014Jul23.PubMedPMID:25053389.

2:YangJ,PradhanRS,RosenLS,GrahamAM,HolenKD,XiongH.Effectofrifampinonthepharmacokinetics,safetyandtolerabilityofnavitoclax(ABT-263),adualinhibitorofBcl-2andBcl-X(L),inpatientswithcancer.JClinPharmTher.2014Jul22.doi:10.1111/jcpt.12193.[Epubaheadofprint]PubMedPMID:25047139.

3:WeiX,ZhouP,LinX,LinY,WuS,DiaoP,XieH,XieK,TangP.MLN2238synergizesBH3mimeticABT-263incastration-resistantprostatecancercellsbyinductionofNOXA.TumourBiol.2014Jul17.[Epubaheadofprint]PubMedPMID:25027405.

4:SuryaniS,CarolH,ChonghaileTN,FrismantasV,SarmahC,HighL,BornhauserB,CowleyMJ,SzymanskaB,EvansK,BoehmI,TonnaE,JonesL,ManeshDM,KurmashevaRT,BillupsC,KaplanW,LetaiA,BourquinJP,HoughtonPJ,SmithMA,LockRB.CellandMolecularDeterminantsofInVivoEfficacyoftheBH3MimeticABT-263againstPediatricAcuteLymphoblasticLeukemiaXenografts.ClinCancerRes.2014Sep1;20(17):4520-31.doi:10.1158/1078-0432.CCR-14-0259.Epub2014Jul10.PubMedPMID:25013123;PubMedCentralPMCID:PMC4154988.

5:PolierG,GiaisiM,KöhlerR,MüllerWW,LutzC,BussEC,KrammerPH,Li-WeberM.TargetingCDK9bywogoninandrelatednaturalflavonespotentiatestheanti-cancerefficacyoftheBcl-2familyinhibitorABT-263.IntJCancer.2014Jun4.doi:10.1002/ijc.29009.[Epubaheadofprint]PubMedPMID:24895203.

6:VlahovicG,KarantzaV,WangD,CosgroveD,RudersdorfN,YangJ,XiongH,BusmanT,MabryM.AphaseIsafetyandpharmacokineticstudyofABT-263incombinationwithcarboplatin/paclitaxelinthetreatmentofpatientswithsolidtumors.InvestNewDrugs.2014Oct;32(5):976-84.doi:10.1007/s10637-014-0116-3.Epub2014Jun5.PubMedPMID:24894650.

7:WangX,GuZ,LiG,ZhangS,CaoZ,YangZ,LiuG.NorcantharidinenhancesABT-263-mediatedanticanceractivityinneuroblastomacellsbyupregulationofNoxa.OncolRep.2014Aug;32(2):716-22.doi:10.3892/or.2014.3228.Epub2014May30.PubMedPMID:24891300.

8:WangB,NiZ,DaiX,QinL,LiX,XuL,LianJ,HeF.TheBcl-2/xLinhibitorABT-263increasesthestabilityofMcl-1mRNAandproteininhepatocellularcarcinomacells.MolCancer.2014Apr30;13:98.doi:10.1186/1476-4598-13-98.PubMedPMID:24779770;PubMedCentralPMCID:PMC4021276.

9:LiJ,ChenY,WanJ,LiuX,YuC,LiW.ABT-263enhancessorafenib-inducedapoptosisassociatedwithAktactivityandtheexpressionofBaxandp21((CIP1/WAF1))inhumancancercells.BrJPharmacol.2014Jul;171(13):3182-95.doi:10.1111/bph.12659.PubMedPMID:24571452;PubMedCentralPMCID:PMC4080973.

10:ChooEF,BoggsJ,ZhuC,LubachJW,CatronND,JenkinsG,SouersAJ,VoormanR.TheroleoflymphatictransportonthesystemicbioavailabilityoftheBcl-2proteinfamilyinhibitorsnavitoclax(ABT-263)andABT-199.DrugMetabDispos.2014Feb;42(2):207-12.doi:10.1124/dmd.113.055053.Epub2013Nov8.PubMedPMID:24212376.